Kazia Therapeutics Limited (NASDAQ: KZIA)
$5.7250
+0.1950 ( +1.51% ) 26.1K
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Market Data
Open
$5.7250
Previous close
$5.5300
Volume
26.1K
Market cap
$25.04M
Day range
$5.5250 - $5.8250
52 week range
$1.8660 - $15.8000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 20-f | Annual reports | 145 | Nov 15, 2024 |
| 6-k | Form 6-K | 1 | Nov 12, 2024 |
| 6-k | Form 6-K | 41 | Nov 04, 2024 |
| nt | Quarterly Reports | 1 | Nov 01, 2024 |
| 6-k/a | Form 6-K | 1 | Oct 24, 2024 |
| 6-k | Form 6-K | 1 | Oct 15, 2024 |
| 6-k | Form 6-K | 3 | Oct 02, 2024 |
| 6-k | Form 6-K | 3 | Sep 23, 2024 |
| 6-k | Form 6-K | 3 | Sep 13, 2024 |
| 6-k | Form 6-K | 3 | Jul 10, 2024 |